About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT03288675

Stepped Care AiTBS 2 Depression Study (Ghent)

Antidepressant-free unipolar melancholic depressed patients (at least stage 2 treatment-resistant) will be selected by a certified psychiatrist, who will administer (semi-)structured clinical intervie...

Lead sponsor: University Hospital, Ghent•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospital, Ghent

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Antidepressant-free unipolar major depression with melancholic features
•Not responding to at least two trials with an antidepressant
•Aged between 18-65 years old

Exclusion Criteria

•Depression with bipolar/psychotic features
•Dysthymia
•Severe personality disorders
•Active substance abuse/dependence within a year prior to inclusion
•Pregnancy or without effective anticonception for the duration of the trial
•ECT non-responder
•No response to more than 9 antidepressants
•Any neurological condition
•Any implanted electronic device susceptible for magnetic field radiation (e.g. pacemaker)
•Any implanted metal device in the head region
•Current or past history of epilepsy
•Neurosurgical interventions
•Known allergic reaction to radiotracers or associated compounds
•Healthy volunteers may be accepted as control subjects.

Related studies

Transcranial Ultrasonic Stimulation in Treatment-resistant Depression : an Open-label Pilot Trial

NCT06085950 · Treatment Resistant Depression

RECRUITINGPhase 3

Ketamine Augmentation of ECT in Treatment-Resistant Depression

NCT07088380 · Major Depressive Disorder, Treatment Resistant Depression

RECRUITINGPhase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454 · Depressive Disorder, Major

RECRUITINGPhase 3

Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

NCT06860958 · Depressive Disorder, Major

Maintenance rTMS for Depression (Maitr-De)

NCT06938841 · Major Depressive Disorder, Treatment Resistant Depression

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 19, 2024Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment68

Start dateOct 2017

Last updatedSep 19, 2024

Condition

Depressive Disorder, Major Treatment Resistant Depression Melancholia

Locations shown

University Hospital Ghent

Ghent, East-Flanders

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions